(PRESS RELEASE) BERLIN, 26-Jul-2021 — /EuropaWire/ — Bayer, a global enterprise with core competencies in the life science fields of…
Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III…